Allogene Therapeutics (ALLO) Total Liabilities (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Total Liabilities data on file, last reported at $117.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 4.49% year-over-year to $117.1 million; the trailing twelve-month figure through Mar 2026 stood at $117.1 million (down 4.49% YoY), and the FY2025 full-year result was $123.4 million, down 2.5% from the prior year.
• Total Liabilities slipped to $117.1 million in Q1 2026, from $123.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $158.1 million in Q1 2023 to a low of $112.8 million in Q1 2022.
• A 5-year average of $133.1 million and a median of $126.5 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 44.92% in 2022 and dropped 20.96% in 2024, its largest moves.
• Tracing ALLO's Total Liabilities over 5 years: stood at $154.7 million in 2022, then fell by 15.57% to $130.6 million in 2023, then dropped by 3.12% to $126.5 million in 2024, then declined by 2.5% to $123.4 million in 2025, then retreated by 5.09% to $117.1 million in 2026.
• Business Quant data shows ALLO's Total Liabilities at $117.1 million in Q1 2026, $123.4 million in Q4 2025, and $124.4 million in Q3 2025.